This study was designed to optimize a method for the identification and quantification of ephedrines in oral fluid (OF) and for its application to subjects taking different doses of pseudoephedrine. Ephedrines use by athletes is banned by World Anti-Doping Agency (WADA), only "in competition" if their concentration in urine exceeds the cutoff limit. The study aimed to establish if there is a correlation in terms of times of elimination and of concentration trends of ephedrine in OF and urine after administration of therapeutic doses of pseudoephedrine to various subjects. Results obtained from excretion studies performed on eight subjects showed reproducible times of disappearance of ephedrines from OF. Pseudoephedrine was generally at low concentrations or undetectable in oral fluid samples 12 h after administration, whereas urine samples collected in the same period of time showed higher ephedrine concentrations and exceeding cutoff values generally between 8 and 24 h after administration of the drug. Within-and between-individual variability was observed in terms of concentrations of pseudoephedrine in OF following the administration of the same dose. Only in the case of sustainedrelease drugs were constant pseudoephedrine concentrations achieved in OF.
Introduction
Oral fluid (OF) is gaining more and more attention as a diagnostic specimen for the determination of recent drug consumption. The presence, and in some cases, the concentration of xenobiotics in this biological fluid are directly related to the corresponding concentration in plasma (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . There is a lack of literature studies on correlations between OF/plasma concentration, particularly for ephedrines. But because their chemical structure is similar to amphetamines, a similar behavior, with concentrations even higher in OF than plasma for these drugs (8) (9) (10) (11) is expected.
In a previous paper, OF was studied as a potential specimen to complement data obtained from urine analysis, focusing the attention on its application for in-competition antidoping tests (15) . We reported data obtained from excretion studies on different drugs. The results showed drugs/metabolites were still detectable in urine, although no longer present in OF. In these cases, this may indicate that the presence of drugs/ metabolites in urine are reflecting the residual elimination phase.
In the present study, we focused our attention on pseudoephedrine, as no data are available in the literature about ephedrines determination in OF. The aim of the study was to develop and validate a sensitive method for ephedrines determination in OF, characterize OF and urine disposition of pseudoephedrine following its administration, and assess withinand between-subject variability in excretion parameters following a single low and high therapeutic dose and multiple high doses; this could be of utility to better consider antidoping violations involving potential pseudoephedrine administration.
Ephedrines are included in the list of prohibited substances of the World Anti-Doping Agency (WADA) with a urinary cutoff of 10 µg/mL for ephedrine and methylephedrine and 5 µg/mL for cathine, the main metabolite of pseudoephedrine (16) . Norephedrine use is currently not prohibited, and pseudoephedrine, which was permitted from 2004, has been for a long time under evaluation by the WADA. A urinary cutoff of 100 µg/mL was previously proposed for this substance, and then was subsequently changed to 150 µg/mL since 2010 (17) . Although pseudoephedrine was not prohibited 2004-2009, some positive antidoping results arise for cathine concentrations of > 5 µg/mL, probably due to pseudoephedrine intake.
In a previous study, we observed high interindividual differences both in the concentration of ephedrines and of their main metabolites in the urine of subjects taking the same dose, in some cases providing concentrations above the cutoff and below the cutoff in other cases (18) . The aim of this study is to evaluate whether the peak concentration time of ephedrines in urine could be correlated with those in OF (and likely in plasma) to help the differentiation between an "in competition" intake of the drug and a remote administration still being in the elimination phase.
Experimental

Chemicals and reagents
Ephedrine-d 3 (used as internal standard) and cathine (norpseudoephedrine) were obtained from LGC Standards (Milano, Italy). Ephedrine, pseudoephedrine, phenylpropanolamine (norephedrine), N-methyl,N-trimethylsylil trifluoroacetamide (MSTFA), tert-buthyl-methyl ether, sodium hydroxide, and trimethylchlorosylane (TMCS) were supplied by Sigma Aldrich (Milano, Italy). Actifed and Reactine were from Pfizer Consumer Health Care (Latina, Italy).
Excretion studies
The study protocol was approved by the local ethical committee of the Ministry of Health for observational studies (Ref.
Prot. 3593/FMB/faf, 23/10/2008). The subjects all used to take over-the-counter medicines containing pseudoephedrine for self-medication, received medical evaluation, and gave in- µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL formed consent prior to the study. Eight subjects, four males (age 23-41 years; weight 76-95 kg) and four females (age 24-40 years; weight 42-55 kg), were enrolled in the excretion studies on pseudoephedrine. They took Actifed (pseudoephedrine 60 mg, triprolidine 2.5 mg) or a galenic preparation containing 60 mg pseudoephedrine. All the subjects were followed after the administration of one single dose of pseudoephedrine (60 mg each). Five of the previously mentioned subjects (four males and one female) also took a 120-mg dose of pseudoephedrine. Among these, one subject could not provide an OF sample because of mouth dryness. For the within-individual study, one subject (male, 95 kg of weight) took doses of 120 mg of pseudoephedrine five times after a washout period of at least five days. For the sustained-release experiment, one subject took reactine (sustained-release tablets of pseudoephedrine 120 mg, cetirizine 5 mg).
In each study, a control urine and OF samples were collected immediately prior to drug administration. All urine produced in the first 12 h and at least the first and last urine of the second day was also collected. OF samples were collected every 2 h for 24 h, except during night.
For the matrix effect and specificity studies, OF samples were collected from 10 laboratory personnel (5 males and 5 females, aged 28-40 years). OF from four subjects taking ibuprofen, diclofenac, paracetamol, and ketoprofen were also tested for evaluating possible interferences.
Sample collection
OF samples were collected using Salivette devices (Sarstedt, Germany). Urine samples were collected in a pharmaceutical reservoir. Both kinds of samples were stored at -20°C until analysis.
Calibration curves
Standard stock solutions of the substances of interest were prepared at concentrations of 1 mg/mL for urine analyses and 1 µg/mL for OF by diluting the reference solutions in methanol and storing at -20°C.
Calibration curves were prepared by adding the appropriate amount of ephedrine, cathine, pseudoephedrine, and norephedrine to 1 mL of blank OF to obtain the following concentrations: 2.5, 5, 10, 25, 50, 100, 500, and 1000 ng/mL. For urine analysis, the concentration added to blank urine samples were 2.5, 5, 10, 15, 25, 50, and 100 µg/mL.
Sample preparation
Twenty-five microliters of ephedrine-d 3 and norephedrined 3 (1 µg/mL for OF and 100 µg/mL for urine) was added to 1 mL of sample (OF or urine), and the mixture was alkalynized by adding two drops of 1 M sodium hydroxide. To this, 200 mg of sodium chloride was added, and the mixture was extracted with 2 mL of tert-buthyl-methyl ether. The organic layer was separated, and 200 mg of anhydrous sodium sulfate was added to remove any residual water. The sample was vortex mixed, transferred to another vial, dried under a gentle stream of nitrogen at room temperature, and derivatized with 50 µL of MSTFA/TMCS (1%) at 70°C for 30 min. One microliter of the derivatized extract was injected directly into the gas chromatograph-mass spectrometer (GC-MS).
Apparatus
The GC-MS system was an Agilent HP6890 GC coupled to a 5973 MS detector (Santa Clara, CA) with a J&W 5% phenylmethylsilicone capillary column (17 m × 0.2-mm i.d., 0.33-µm film thickness). Chromatographic conditions were as follows: the oven temperature was held at 130°C for 1 min, increased to 200 at 8°C/min, increased to 280°C at 40°C/min and held 2 min; the injection port was set at 270°C in split mode (split ratio 20:1) for urine analysis and in splitless mode for OF; and helium was used as the carrier gas at a constant pressure of 20 psi.
The mass detector operated in electron impact ionization at 70 eV in scan mode for urine analysis (scan range 47-400) and in SIM mode for OF analysis. Ions selected were at m/z 116, 117, 163, 280 for cathine; 119, 120, 283 for norephedrine-d 3 ; 130, 131, 220, 294 for ephedrine/pseudoephedrine; and 133, 134, 223, 297 for ephedrine-d 3 . Underlined ions were used for quantification of ephedrines in OF. 
Method validation
In this paper, only validation for OF will be presented. Validation data for urine analysis are reported elsewhere (18) .
The method for qualitative and quantitative analysis of ephedrines in OF and urine was validated taking into consideration the following parameters: limit of detection (LOD) and of quantification (LOQ), specificity, linearity, intra-and interassay accuracy, repeatability, and intermediate precision (interday repeatability). The LOD was defined as the lowest concentration of the analyte with an identifiable peak with a signal-to-noise ratio > 3 for at least three ions. The LOQ was defined as the lowest concentration of the analyte that could be quantified with an acceptable coefficient of variation (CV%) (< 10) with a signal-to-noise ratio always > 10 for at least three diagnostic ions. Matrix effect was studied analyzing 10 blank samples and studying the presence of interfering peaks at the retention times of the analytes. Specificity was studied analyzing two different blank OF samples spiked with 1 µg/mL of amphetamine, methamphetamine, phenmetrazine, phendimetrazine, fenfluramine, ethylamphetamine, fentermine, propilhexedrine, amphepramone, dimethamphetamine, methylendioxymethamphetamine, and methylendioxyethylamphetamine as well as samples from subjects taking nonsteroidal anti-inflamatory drugs (ibuprofen, diclofenac, paracetamol, and ketoprofen).
Linearity was determined by the preparation of calibration curves using concentrations of 5, 10, 25, 50, 100, and 500 ng/mL (as well as 1000 ng/mL for pseudoephedrine) considering the area ratio between the analytes and their correspondent deuterated internal standard (ephedrine-d 3 for ephedrine and pseudoephedrine and norephedrine-d 3 for cathine and norephedrine).
Intraassay repeatability (CV%) and accuracy (mean relative error) were determined at two concentrations (10 and 25 ng/mL for ephedrine, norephedrine, and cathine and 25 and 100 ng/mL for pseudoephedrine) using five replicates each. Interday repeatability was determined analyzing five replicate samples at the concentrations mentioned previously on three different days. The stability of the derivatized compounds was tested by quantifying the same extracts for three consecutive days.
Results
The aim of this work was to implement the method described for stimulants analysis in OF in order to have better performance for the separation and quantification of ephedrines.
The present method allows the complete separation of the diastereomers (ephedrine/pseudoephedrine, cathine/ norephedrine). No interfering peaks were detected at the expected retention times of the analytes of interest in 10 blank samples. Related drugs, such as amphetamines and anorectic compounds and common over-the-counter anti-inflammatory preparations, did not interfere with ephedrines. A good linearity was observed for all the analytes in OF in the range 5-500 ng/mL (1000 ng/mL for pseudoephedrine). No carryover effect was observed after injection of the higher levels of calibration.
Validation results for OF analysis are summarized in Table I . The method was then applied to real OF samples obtained from excretion studies and analyzed in parallel with the correspondent urine samples. Results obtained after administration of 60 and 120 mg of pseudoephedrine are shown in Tables  II-VII and Figures 1 and 2 .
The peak of salivary concentration of pseudoephedrine was generally between 2 and 4 h after administration, except for subject 3 who showed a peak of concentration at 8-12 h after administration. His urinary levels of both pseudoephedrine and metabolite were the lowest of the study (maximum value found was 66 µg/mL of pseudoephedrine and 2.8 µg/mL of cathine both for 60 and 120 mg administrations). On the contrary, urinary peak of excretion was generally between 8 and 12 h after administration with values in some cases exceeding the cutoff at 12 h and up to 24 h after the administration.
At the peak of concentration, mean OF values of pseudoephedrine were 95 ng/mL (n = 7, excluding an outlier) (min- imum 15 ng/mL, maximum 215 ng/mL) in the case of 60 mg dose and 150 ng/mL (n = 4, minimum 22 ng/mL, maximum 365 ng/mL) after a 120-mg dose. Salivary data in general showed highly variable concentration values both in different subjects and in the same individuals, especially at the peak of concentration. On the contrary, between 8 and 12 h after administration of the drug, results are more reproducible.
In the case of the administration of a sustained-release formulation containing 120 mg of pseudoephedrine, after peaks of 550 ng/mL (reached only 2 h after each administration), OF samples showed quite constant concentrations of pseudoephedrine 4 h after the administration up to the following dose (n = 10, mean value 360 ng/mL, CV% 20). Urine samples showed values of pseudoephedrine sometimes exceeding 100 µg/mL but with cathine never over 5 µg/mL (n = 8, mean pseudoephedrine value 105 µg/mL, minimum 36 µg/mL, maximum 163 µg/mL).
Conclusions
OF concentrations of pseudoephedrine showed high interand intraindividual variability. At the peak of excretion, mean concentrations obtained from 120-mg administrations are almost twice the mean concentrations obtained from 60-mg doses. Interindividual comparable concentrations were obtained only in the elimination phase between 6 and 12 h after drug intake.
Urine samples collected in the same period also showed, in the same way, high variability of concentrations. The higher pseudoephedrine concentrations exceeding cutoff values were, however, generally between 8 and 24 h after administration of the drug. This means that anti-doping controls performed 24 h after administration of a therapeutic dose of pseudoephedrine can lead to an "adverse analytical finding" for cathine or pseudoephedrine, although the drug is no longer in circulation. Constant pseudoephedrine concentrations were measured in OF only in the case of sustained-release medications. In this case, urinary concentrations were never higher than the cutoff level for cathine but in some instances higher than 100 µg/mL for pseudoephedrine.
These results show that in many instances, elevated urinary concentrations of a drug or its metabolite do not overlap with its presence in OF. Although oral fluid data for pseudoephedrine are not reproducible in terms of both inter-and intraindividual concentrations, they are more reproducible in terms of disappearance and times of peak of concentration. Therefore, they show a high diagnostic power, if coupled to urine, in all those cases in which it is necessary to establish whether a person is still under the effect of a drug and a blood sample is unavailable. In the specific case of "in competition" antidoping tests, OF analysis can help to establish if the drug and/or its main active metabolite is effectively active during the competition or simply being excreted after a previous administration.
